Agbeko Djagadou Kodjo, Toyi Tchamdja, Lihanimpo Djalogue, Dzidzonu Némi Komi, Laconi Kaaga, Abago Balaka, Awalou Djibril Mohaman
Service de Médecine Interne, Faculté des Sciences de la Santé, Université de Lomé, Togo.
Pan Afr Med J. 2019 Dec 18;34:203. doi: 10.11604/pamj.2019.34.203.20600. eCollection 2019.
Antiretroviral drugs are responsible for side effects or undesirable effects. These may include redistribution of adipose tissue and disorders of the lipid or carbohydrate metabolism. Given the growing number of people living with HIV (PLHIV) on antiretroviral therapy, it is necessary to assess the frequency of disorders of carbohydrate and lipid metabolism in patients who are on antiretroviral therapy (ARV). Our analysis focused on 493 patients with HIV/AIDS and on ARV treated in the Medical Centre of the ONG Espoir Vie Togo, Lomé. Paraclinical data such as blood glucose, serum total cholesterol, triglycerides, HDL cholesterol and LDL cholesterol were studied. The study showed the following anomalies: hypercholesterolemia, LDL hypercholesterolemia, HDL-hypocholesterolemia were found in 41.4%, 23.5% and 17.4% of patients respectively. The incidence of hyperglycemia was 12.4%. It is important to note that the incidence of lipido carbohydrate disorders was higher in patients receiving treatment schedule including protease inhibitors. The study also highlighted that 31.2% of patients with disorders of carbohydrate and lipid metabolism were overweight or obese. The incidence of these disorders differs depending on whether patients were under triple therapy including protease inhibitors or not.
抗逆转录病毒药物会引发副作用或不良影响。这些副作用可能包括脂肪组织重新分布以及脂质或碳水化合物代谢紊乱。鉴于接受抗逆转录病毒治疗的艾滋病毒感染者(PLHIV)人数不断增加,有必要评估接受抗逆转录病毒治疗(ARV)的患者中碳水化合物和脂质代谢紊乱的发生率。我们的分析聚焦于493例在多哥洛美ONG Espoir Vie医疗中心接受抗逆转录病毒治疗的艾滋病毒/艾滋病患者。研究了血糖、血清总胆固醇、甘油三酯、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇等临床辅助数据。研究显示了以下异常情况:分别有41.4%、23.5%和17.4%的患者出现高胆固醇血症、低密度脂蛋白高胆固醇血症、高密度脂蛋白低胆固醇血症。高血糖症的发生率为12.4%。需要注意的是,在接受包括蛋白酶抑制剂的治疗方案的患者中,脂质碳水化合物紊乱的发生率更高。该研究还强调,31.2%的碳水化合物和脂质代谢紊乱患者超重或肥胖。这些紊乱的发生率因患者是否接受包括蛋白酶抑制剂的三联疗法而有所不同。